Antitumor and antiangiogenic compound. DNA alkylating agent. Induces G2/M arrest and apoptosis through adduction of a methyl group to O6 position of guanine in genomic DNA. Inactivates DNA repair protein O(6)-alkylguanine DNA alkyltransferase (AGT) in base excision repair (BER) pathway. Chemotherapeutic agent. Modifies drug resistance.
Product Details
| Alternative Name: | 8-Carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one |
| |
| Formula: | C6H6N6O2 |
| |
| MW: | 194.2 |
| |
| CAS: | 85622-93-1 |
| |
| MI: | 14: 9139 |
| |
| RTECS: | NJ5927050 |
| |
| Purity: | ≥98% (HPLC) |
| |
| Appearance: | White to off-white crystalline powder. |
| |
| Solubility: | Soluble in DMSO; slightly soluble in water. |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | -20°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Improved effects of honokiol on temozolomide-induced autophagy and apoptosis of drug-sensitive and -tolerant glioma cells: C.C. Chio, et al.; BMC Cancer
18, 379 (2018),
Abstract;
Full Text
Direct modification of the 5-HT3 receptor current by some anticancer drugs: Y. Nakamura, et al.; Eur. J. Pharmacol.
821, 21 (2017),
Abstract;
Hedgehog/Gli1 signaling pathway regulates MGMT expression and chemoresistance to temozolomide in human glioblastoma: K. Wang, et al.; Cancer Cell Int.
17, 117 (2017),
Abstract;
Full Text
Underexpression of HOXA11 Is Associated with Treatment Resistance and Poor Prognosis in Glioblastoma: Y.B. Se, et al.; Cancer Res. Treat.
49, 387 (2017),
Abstract;
Full Text
Concomitant treatment of brain metastasis with whole brain radiotherapy [WBRT] and temozolomide [TMZ] is active and improves quality of life: R. Addeo, et al.; BMC Cancer
7, 18 (2007),
Abstract;
Full Text
Temozolomide for the treatment of metastatic melanoma: a systematic review: I. Quirt, et al.; Oncologist
12, 1114 (2007), (Review),
Abstract;
Full Text
Mutagenic potential of temozolomide in bone marrow cells in vivo: H. Geiger, et al.; Blood
107, 3010 (2006),
Abstract;
Full Text
Inhibition of angiogenesis by non-toxic doses of temozolomide: H. Kurzen, et al.; Anticancer Drugs
14, 515 (2003),
Abstract;
Temozolomide induces apoptosis and senescence in glioma cells cultured as multicellular spheroids: W. Gunther, et al.; Br. J. Cancer
88, 463 (2003),
Abstract;
Combined treatment with temozolomide and poly(ADP-ribose) polymerase inhibitor enhances survival of mice bearing hematologic malignancy at the central nervous system site: L. Tentori, et al.; Blood
99, 2241 (2002),
Abstract;
Full Text
p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells: Y. Hirose, et al.; Cancer Res.
61, 1957 (2001),
Abstract;
Full Text
Temozolomide: a novel oral alkylating agent: S.J. Danson & M.R. Middleton; Expert Rev. Anticancer Ther.
10, 13 (2001),
Abstract;
Antitumor Imidazotetrazines. 35. New Synthetic Routes to the Antitumor Drug Temozolomide: Y. Wang, et al.; J. Org. Chem.
62, 7288 (1997),
Abstract;
Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials: E.S. Newlands, et al.; Cancer Treat. Rev.
23, 35 (1997),
Abstract;
Antitumor imidazotetrazines--XV. Role of guanine O6 alkylation in the mechanism of cytotoxicity of imidazotetrazinones: M.J. Tisdale; Biochem. Pharmacol.
36, 457 (1987),
Abstract;
Antitumor imidazotetrazines. 1. Synthesis and chemistry of 8-carbamoyl-3-(2-chloroethyl)imidazo[5,1-d]-1,2,3,5-tetrazin-4(3 H)-one , a novel broad-spectrum antitumor agent: M.F. Stevens, et al.; J. Med. Chem.
27, 196 (1984),
Abstract;
